Clinical Trial Details

A randomized phase II trial of carboplatin with or without nivolumab in first-line metastatic triple-negative breast cancer (DFCI/HCC 17-512)

This research study is studying a drug called Carboplatin with or without another study drug, Nivolumab as a possible treatment for triple-negative breast cancer that has spread to other parts of the body.

Learn more

Principal Investigator(s)


Dana-Farber Cancer Institute


Mary Miller, LPN at 203-358-8879 or [email protected]


Our website uses cookies

This website uses cookies to give you the very best experience. Your continued use of this site is considered permission by you to use cookies in this manner. Please review our Privacy Policy and Terms of Use for more information about the data we collect and the types of cookies we use. Please note, if you link off our website to a 3rd party site of any kind, that website has its own terms and conditions.